Pictured: Atmo Biosciences CEO Mal Hebblewhite holds the ingestible Atmo Gas Capsule that continuously measures clinically important gaseous biomarkers as it passes through the gut.
BMTH Round: Third
Project Title: Application of Atmo ingestible gas sensing capsule to Irritable Bowel Syndrome
Atmo Biosciences is developing an application of its ingestible gas sensing capsule and cloud platform to diagnose Irritable Bowel Syndrome (IBS) and Small Intestinal Bacterial Overgrowth (SIBO).
IBS develops in as many as 1 in 5 adults. It is associated with debilitating symptoms, significant morbidity and high healthcare costs. Diagnosis, treatment, and management of IBS is challenging because it is a syndrome based on symptoms – with no definitive test or biomarker.
Atmo Biosciences is a clinical stage digital health business that is addressing an unmet clinical need to interrogate and monitor microbiome function. This will allow better diagnosis and development of personalised therapies for gastrointestinal disorders including IBS, SIBO, inflammatory bowel disease and others.
Atmo is underpinned by a world-first ingestible electronic capsule that senses clinically valuable gaseous biomarkers produced by the microbiome as it travels through the gastrointestinal tract. The data is transmitted in real-time to a cloud platform for aggregation and analysis.
The BMTH project will demonstrate the commercial application of the Atmo platform in identifying IBS subtypes and diagnosing SIBO. This includes developing machine learning algorithms to determine the constituents of complex gas mixtures relevant to IBS and SIBO, and conducting a clinical trial to validate the algorithm against current diagnostic standards.
Visit Atmo Biosciences for more information.
LinkedIn: Atmo Biosciences
Project Partners: Monash University, Alfred Health, University of Queensland, Princess Alexandra Hospital, Brisbane, RMIT University & Planet Innovation
Contact: Malcolm Hebblewhite